{"url_path":"/sec/clpt/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1285550/0001193125-26-221890-index.html","accession_number":"0001193125-26-221890","cik":"0001285550","ticker":"CLPT","issuer_name":"ClearPoint Neuro, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1285550/0001193125-26-221890-index.html","primary_entity_key":"0001285550","primary_entity_name":"ClearPoint Neuro, Inc."},"word_count":499,"has_tables":true,"body_markdown":"ITEM 6. EXHIBITS.\n\nThe exhibits listed below are filed, furnished, or incorporated by reference as part of this Quarterly Report.\n\nExhibit\n\nNumber\n\n \n\nExhibit Description\n\n \n\n \n\n \n\n3.1\n\n \n\n[Amended and Restated Certificate of Incorporation of MRI Interventions, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Quarterly Report on Form 10-Q, filed with the SEC on May 11, 2012).](https://www.sec.gov/Archives/edgar/data/1285550/000143774912004904/ex3-1.htm)\n\n3.2\n\n \n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MRI Interventions, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, filed with the SEC on June 8, 2015).](https://www.sec.gov/Archives/edgar/data/1285550/000143774915011919/ex3-1.htm)\n\n3.3\n\n \n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of MRI Interventions, Inc. (incorporated by reference to Exhibit 3.3 to the Company's Registration Statement on Form S-1, filed with the SEC on August 2, 2016).](https://www.sec.gov/Archives/edgar/data/1285550/000153442416000916/ex3-3.htm)\n\n3.4\n\n \n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, filed with the SEC on February 12, 2020).](https://www.sec.gov/Archives/edgar/data/1285550/000117152020000061/ex3-1.htm)\n\n3.5\n\n \n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, filed with the SEC on May 25, 2023).](https://www.sec.gov/Archives/edgar/data/1285550/000128555023000050/clptcertificateofamendment.htm)\n\n3.6\n\n \n\n[Fourth Amended and Restated Bylaws of ClearPoint Neuro, Inc. (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed with the SEC on December 14, 2022).](https://www.sec.gov/Archives/edgar/data/1285550/000128555022000082/finalproposed-clptbylaws.htm)\n\n31.1*\n\n \n\n[Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) Under the Securities Exchange Act of 1934](clpt-ex31_1.htm)\n\n31.2*\n\n \n\n[Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) Under the Securities Exchange Act of 1934](clpt-ex31_2.htm)\n\n32+\n\n \n\n[Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Rule 13a-14(b) under the Securities Exchange Act of 1934 and Section 1350 of Chapter 60 of Title 18 of the United States Code](clpt-ex32.htm)\n\n101.INS\n\n \n\nInline XBRL Instance Document – the instance document does not appear in the Interactive Data File as its XBRL tags are embedded within the Inline XBRL document.\n\n101.SCH\n\n \n\nInline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents\n\n104\n\n \n\nCover page formatted as Inline XBRL and contained in Exhibit 101\n\n*\nFiled herewith.\n\n+ This certification is being furnished solely to accompany this Quarterly Report pursuant to 18 U.S.C. Section 1350, and it is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934 and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.\n\n31\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\nDate: May 13, 2026\n\n \n\n \n\n \n\n \n\n \n\n \n\nCLEARPOINT NEURO, INC.\n\n \n\n \n\n \n\n \n\nBy:\n\n/s/ Joseph M. Burnett\n\n \n\n \n\nJoseph M. Burnett\n\n \n\n \n\nChief Executive Officer\n\n \n\n \n\n(Principal Executive Officer)\n\n \n\n \n\n \n\n \n\nBy:\n\n/s/ Danilo D’Alessandro\n\n \n\n \n\nDanilo D’Alessandro\n\n \n\n \n\nChief Financial Officer\n\n \n\n \n\n(Principal Financial Officer and Principal Accounting Officer)\n\n \n\n32"}